MX2023002325A - Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. - Google Patents

Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Info

Publication number
MX2023002325A
MX2023002325A MX2023002325A MX2023002325A MX2023002325A MX 2023002325 A MX2023002325 A MX 2023002325A MX 2023002325 A MX2023002325 A MX 2023002325A MX 2023002325 A MX2023002325 A MX 2023002325A MX 2023002325 A MX2023002325 A MX 2023002325A
Authority
MX
Mexico
Prior art keywords
hair loss
deuterated
treatment
loss disorders
jak inhibitors
Prior art date
Application number
MX2023002325A
Other languages
English (en)
Inventor
Philip B Graham
Virginia Braman
Amanda T Wagner
James V Cassella
Vinita Uttamsingh
Hehn Jana Von
Colleen E Hamilton
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023002325(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Publication of MX2023002325A publication Critical patent/MX2023002325A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un método para tratar trastornos de pérdida del cabello en un sujeto que se tratan de manera beneficiosa administrando un inhibidor de JAK1 y/o JAK2. El método comprende administrar al sujeto una cantidad en el intervalo de aproximadamente 4 mg a aproximadamente 50 mg del Compuesto (I): (ver Fórmula) Compuesto (1) o una sal farmacéuticamente aceptable de éste. Esta invención también proporciona composiciones que comprende el Compuesto (I) y el uso de tales composiciones en los métodos descritos.
MX2023002325A 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. MX2023002325A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US201762492758P 2017-05-01 2017-05-01

Publications (1)

Publication Number Publication Date
MX2023002325A true MX2023002325A (es) 2023-03-22

Family

ID=60203616

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2018013347A MX2018013347A (es) 2016-05-04 2017-05-04 Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002325A MX2023002325A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002323A MX2023002323A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021014175A MX2021014175A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002321A MX2023002321A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002324A MX2023002324A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018013347A MX2018013347A (es) 2016-05-04 2017-05-04 Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2023002323A MX2023002323A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021014175A MX2021014175A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002321A MX2023002321A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002324A MX2023002324A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Country Status (10)

Country Link
US (2) US10561659B2 (es)
EP (1) EP3452039B1 (es)
JP (2) JP7145080B2 (es)
KR (2) KR20230086814A (es)
CN (1) CN109069493A (es)
AU (2) AU2017261286B2 (es)
BR (1) BR112018072339A2 (es)
CA (1) CA3022519A1 (es)
MX (6) MX2018013347A (es)
WO (1) WO2017192905A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561659B2 (en) * 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
IL302401A (en) 2020-10-28 2023-06-01 Sun Pharmaceutical Ind Inc Regimens for the treatment of hair loss disorders with faded JAC inhibitors
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
EP4384175A1 (en) 2021-08-11 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
NZ528689A (en) 2001-05-03 2005-03-24 F Pharmaceutical dosage form of amorphous nelfinavir mesylate
AU2005292339A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
PT3184526T (pt) 2005-12-13 2018-12-19 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
PT2635299T (pt) * 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
PL2830662T3 (pl) 2012-03-29 2019-02-28 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
US20150197525A1 (en) * 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
EP2882751B1 (en) * 2012-07-30 2018-06-27 Concert Pharmaceuticals Inc. Deuterated ibrutinib
SG11201503695XA (en) * 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN110229159B (zh) * 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
EP3102190A4 (en) 2014-02-07 2017-09-06 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
US10561659B2 (en) * 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors

Also Published As

Publication number Publication date
US10561659B2 (en) 2020-02-18
US20190160068A1 (en) 2019-05-30
MX2023002321A (es) 2023-03-22
MX2023002323A (es) 2023-03-22
JP7145080B2 (ja) 2022-09-30
AU2017261286B2 (en) 2023-03-23
BR112018072339A2 (pt) 2019-02-19
AU2017261286A1 (en) 2018-11-22
JP2019516684A (ja) 2019-06-20
AU2023201112A1 (en) 2023-03-30
WO2017192905A1 (en) 2017-11-09
EP3452039B1 (en) 2024-07-03
JP2022171838A (ja) 2022-11-11
EP3452039A1 (en) 2019-03-13
US20200222408A1 (en) 2020-07-16
CA3022519A1 (en) 2017-11-09
MX2021014175A (es) 2022-01-04
MX2023002324A (es) 2023-03-22
KR20190003711A (ko) 2019-01-09
EP3452039A4 (en) 2019-12-25
MX2018013347A (es) 2019-09-02
CN109069493A (zh) 2018-12-21
KR20230086814A (ko) 2023-06-15

Similar Documents

Publication Publication Date Title
MX2021014175A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
EA202190630A1 (ru) Способы комбинированной терапии
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2021002521A (es) Dimetilaminoazetidinaminas como inhibidores de jak.
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
MX2022001004A (es) Inhibidores de enzimas.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2021013602A (es) Inhibidores de jak.
MX2021001612A (es) Compuestos utiles en terapia del vih.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
MX2020008413A (es) Composiciones para la prevencion o tratamiento de la uveitis.
MX2023005027A (es) Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados.
PH12020551620A1 (en) Compositions for preventing or treating dry eye
EA202190751A1 (ru) Способы лечения миелопролиферативных расстройств